参考文献/References:
[1]边策,綦小蓉,姚奎,等.新辅助化疗对晚期卵巢癌治疗应用价值的评估及多因素分析[J].实用妇产科杂志,2016,32(4):266-271.
[2]曾龙佳,卢芳芳,易素祎,等.晚期卵巢癌的新辅助化疗应用[J].中国妇幼保健,2016,31(14):2975-2978.
[3]阮冠宇,孙蓬明,林小梅.贝伐单抗联合化疗治疗卵巢癌有效性及安全性分析[J].中国妇产科临床杂志,2016,17(4):323-327.
[4]卢淮武,谢玲玲,林仲秋.《2016NCCN卵巢癌临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2016,32(8):761-768.
[5]孙建衡.妇科恶性肿瘤放射治疗学[M].北京.协和医科大学出版社,2002:45-47.
[6]宋倪媛,陈徐,李霞,等.紫杉醇联合洛铂治疗晚期卵巢癌的效果及其对ERCC1、β-catenin、β-tubulin Ⅲ表达的影响[J].中国医药导报,2016,13(6):115-118.
[7]唐慕菲,朱余兵,李杨,等.紫杉醇脂质体与紫杉醇分别联合卡铂治疗卵巢癌疗效的Meta分析[J].中国药师,2018,21(4):52-54.
[8]Fernández A,Salgado M,García A,et al.Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study[J].BMC Cancer,2018,18(1):1185.
[9]梁楠楠,林琳,郗轶楠.紫杉醇与卡铂联合参麦注射液对中晚期卵巢癌患者外周血T细胞亚群及血清标志物变化的影响[J].中国肿瘤临床与康复,2018,25(3):11-13.
[10]李桂梅,刘冬梅,平伟,等.紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗卵巢癌的疗效比较[J].中国肿瘤临床与康复,2016,23(5):563-565.
[11]侯文杰,徐建英,池迟,等.脂质体紫杉醇联合卡铂与紫杉醇联合卡铂治疗上皮性卵巢癌的疗效和安全性比较[J].肿瘤防治研究,2018,45(6):82-84.
[12]陈璐,周黎,李伊莎.卡铂联合紫杉醇对老年晚期卵巢癌患者的临床疗效及血清HE4、CA125水平的影响[J].世界临床药物,2017,38(4):252-256.
[13]张富斌,崔李宁,徐科君.紫杉醇脂质体与传统紫杉醇联合卡铂治疗卵巢癌的疗效及不良反应的对比分析[J].中华全科医学,2017,15(5):808-810.
相似文献/References:
[1]彭玉龙,张 露,陈荣辉,等.吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察[J].医学信息,2018,31(11):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Journal of Medical Information,2018,31(07):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
[2]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Journal of Medical Information,2020,33(07):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[3]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Journal of Medical Information,2020,33(07):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
[4]王小毛,黄 晶,石 峰.金龙胶囊对耐紫杉醇及卡铂卵巢癌H08910细胞的逆转及增敏作用[J].医学信息,2020,33(04):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
WANG Xiao-mao,HUANG Jing,SHI Feng.Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells[J].Journal of Medical Information,2020,33(07):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
[5]吴仁瑞,汪 琛,刘 超.紫杉醇联合卡铂方案同步放化疗在Ⅲ期胃食管结合部癌中的近期疗效和安全性[J].医学信息,2022,35(20):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]
WU Ren-rui,WANG Chen,LIU Chao.Short-term Efficacy and Safety of Concurrent Chemoradiotherapy with Paclitaxel and Carboplatin in Stage Ⅲ Gastroesophageal Junction Cancer[J].Journal of Medical Information,2022,35(07):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]
[6]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Journal of Medical Information,2023,36(07):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]